



Implementing TMB measurement in clinical practice: considerations on assay requirements

Reinhard Büttner,¹ John W Longshore,² Fernando López-Ríos,³ Sabine Merkelbach-Bruse,⁴ Nicola Normanno,⁵ Etienne Rouleau,⁶ Frédérique Penault-Llorca^{7,8}

To cite: Büttner R, Longshore JW, López-Ríos F, *et al.* Implementing TMB measurement in clinical practice: considerations on assay requirements. *ESMO Open* 2019;4:e000442. doi:10.1136/esmoopen-2018-000442

Received 3 September 2018
Accepted 21 September 2018

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

¹Institute of Pathology, University Hospital Cologne, Cologne, Germany

²Atrium Health, Carolinas Pathology Group, Charlotte, North Carolina, USA

³Laboratorio de Dianas Terapéuticas, Hospital Universitario HM Sanchinarro, Madrid, Spain

⁴Institute of Pathology, University Hospital Cologne, Cologne, Germany

⁵Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS, Naples, Italy

⁶Department of Pathology and Medical Biology, Institut Gustave Roussy, Villejuif, France

⁷Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France

⁸UMR INSERM 1240 Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont-Auvergne, Clermont-Ferrand, France

Correspondence to

Prof Frédérique Penault-Llorca; Frederique.penault-llorca@clermont.unicancer.fr

ABSTRACT

Clinical evidence demonstrates that treatment with immune checkpoint inhibitor immunotherapy agents can have considerable benefit across multiple tumours. However, there is a need for the development of predictive biomarkers that identify patients who are most likely to respond to immunotherapy. Comprehensive characterisation of tumours using genomic, transcriptomic, and proteomic approaches continues to lead the way in advancing precision medicine. Genetic correlates of response to therapy have been known for some time, but recent clinical evidence has strengthened the significance of high tumour mutational burden (TMB) as a biomarker of response and hence a rational target for immunotherapy. Concordantly, immune checkpoint inhibitors have changed clinical practice for lung cancer and melanoma, which are tumour types with some of the highest mutational burdens. TMB is an implementable approach for molecular biology and/or pathology laboratories that provides a quantitative measure of the total number of mutations in tumour tissue of patients and can be assessed by whole genome, whole exome, or large targeted gene panel sequencing of biopsied material. Currently, TMB assessment is not standardised across research and clinical studies. As a biomarker that affects treatment decisions, it is essential to unify TMB assessment approaches to allow for reliable, comparable results across studies. When implementing TMB measurement assays, it is important to consider factors that may impact the method workflow, the results of the assay, and the interpretation of the data. Such factors include biopsy sample type, sample quality and quantity, genome coverage, sequencing platform, bioinformatic pipeline, and the definitions of the final threshold that determines high TMB. This review outlines the factors for adoption of TMB measurement into clinical practice, providing an understanding of TMB assay considerations throughout the sample journey, and suggests principles to effectively implement TMB assays in a clinical setting to aid and optimise treatment decisions.

BACKGROUND

Immunotherapy agents have demonstrated significant clinical benefit across multiple tumours; however, as with most therapeutic agents, there is a need for robust biomarkers that predict which patients are most likely to

respond to immunotherapy.^{1 2} Programmed death ligand 1 (PD-L1) expression emerged as a biomarker for immunotherapy,^{3–5} although challenges with PD-L1 testing exist. PD-L1 immunohistochemistry assays can use different reagents and platforms, and standardisation between them is required.⁵ There is also uncertainty about whether to assess PD-L1 expression on tumour cells and/or immune cells.⁶ Furthermore, PD-L1 expression alone is often insufficient for predicting response.⁷ Despite the challenges, PD-L1 immunohistochemistry assays are approved for companion and complementary testing with immunotherapy.⁵

Clinical studies to dissect the genetic makeup of tumours revealed that patients with high TMB have increased response rates and improved outcomes to treatment with immunotherapy compared with patients with lower TMB (table 1). This concept was recently validated in a phase III trial with a coprimary endpoint of progression-free survival in patients with high TMB (≥10 mutations/megabase (mut/Mb) measured by the FoundationOne CDx assay^{8 9}).

TMB is defined as the total number of somatic mutations in a defined region of a tumour genome, but the precise definition varies with the sequenced region size and localisation, and the nature of the mutations included.^{10 11} Testing for genomic alterations, including TMB, is currently performed using next-generation sequencing (NGS). Several NGS approaches exist and the target region ranges from genome-wide analysis (whole genome sequencing (WGS)) to whole exome sequencing (WES, covering the entire coding regions of genes in the genome) and large targeted gene panels (table 1). Many initial clinical studies used WES for TMB assessment, and WES of tumour versus germline DNA is currently considered a reference standard. However, there are many commercial

Table 1 Summary of clinical evidence demonstrating TMB as a biomarker for response to immunotherapy

Immunotherapy agent and tumour type	Study/trial*	TMB assay used	Type of benefit
Nivolumab			
NSCLC (1 L)	CheckMate 026 ⁵²	WES	ORR, PFS
NSCLC	Flatiron Health ¹¹⁷	Foundation CGP panel	OS
Melanoma (1 L or 2 L)	CheckMate 038 ²²	WES	ORR, OS, PFS
Melanoma	CheckMate 064 ²³	WES	ORR, OS
Bladder	CheckMate 275 ⁸³	WES	ORR, OS, PFS
GBM	Bouffet <i>et al</i> , 2016 ¹¹⁸	WES	DRR
Ipilimumab			
Melanoma	Van Allen <i>et al</i> , 2015 ¹¹⁹	WES	CBR
	Snyder <i>et al</i> , 2014 ⁸⁶	WES	CBR, OS
Nivolumab and ipilimumab in combination			
NSCLC (1 L)	CheckMate 012 ³⁵	WES	ORR, DCB, PFS
NSCLC (1 L)	CheckMate 227† ⁸	FoundationOne CDx	ORR, PFS
NSCLC (1 L)	CheckMate 568 ⁹	FoundationOne CDx	ORR
SCLC (2 L)	CheckMate 032 ⁸⁴	WES	ORR, OS, PFS
Pembrolizumab			
NSCLC (1 L)	KEYNOTE-001 ³⁶	WES	ORR, DCB, PFS
CRC	Le <i>et al</i> , 2015 ⁴⁴	WES	ORR, PFS
Multiple solid tumours	KEYNOTE-012/KEYNOTE-028 ¹²⁰ ¹²¹	WES	ORR
Atezolizumab			
NSCLC (2 L)	POPLAR/OAK ^{87 88}	Foundation bTMB	OS, PFS
NSCLC (2 L)	POPLAR/FIR/BIRCH ⁸⁵	FoundationOne	ORR, OS, PFS
NSCLC (1 L)	BFAST and B-F1RST ^{122–124}	Foundation bTMB	DOR, ORR, PFS, OS
NSCLC	Rizvi <i>et al</i> , 2018 ⁵⁶	WES	DCB, ORR, PFS
Bladder (1 L or 2 L)	IMvigor 210 ^{125 126}	Foundation CGP panel	ORR, OS
		FoundationOne	ORR
Bladder (2 L)	IMvigor 211 ¹²⁷	FoundationOne	OS
Bladder	Snyder <i>et al</i> , 2017 ¹²⁸	WES	PFS
Multiple agents			
NSCLC	Rozenblum <i>et al</i> , 2017 ¹²⁹	FoundationOne and Guardant360	ORR
Melanoma	Johnson <i>et al</i> , 2016 ⁵³	FoundationOne	ORR, OS, PFS
	Hugo <i>et al</i> , 2016 ⁴⁵	WES	OS
Multiple solid tumours	Goodman <i>et al</i> , 2017 ¹³⁰	FoundationOne	ORR, OS, PFS
	Yarchoan <i>et al</i> , 2017 ²⁵	Various (not reported)	ORR
Multiple solid tumours (2 L)	Bonta <i>et al</i> , 2017 ¹³¹	FoundationOne	ORR

*Ongoing atezolizumab, durvalumab and avelumab trials have primary completion dates in 2019 and 2020.

†CheckMate 227 has monotherapy and combination therapy arms in the study design.

CBR, clinical benefit rate; CGP, comprehensive genomic profiling; CRC, colorectal cancer; DCB, durable clinical benefit; DOR, duration of response; DRR, durable response rate; GBM, glioblastoma multiforme; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SCLC, small cell lung cancer; TMB, tumour mutational burden; WES, whole exome sequencing.

gene panel assays and laboratory-developed tests (LDTs) being used. The US Food and Drug Administration (FDA) recently approved the gene panel assay FoundationOne

CDx¹² and authorised MSK-IMPACT¹³ for profiling solid tumours for genomic alterations in a clinical setting, and many other assays are currently available for research use

only. As well as testing for actionable mutations, these assays can test for TMB in parallel.^{14 15} However, they can differ in their methodology (eg, enrichment approach, sequencing system, bioinformatic pipeline), the number of genes and types of mutations included (eg, synonymous and/or nonsynonymous), and the recommendations for interpretation of results. For example, TMB is defined in FoundationOne CDx as the number of somatic, coding, base substitutions (synonymous and nonsynonymous) and short insertions and deletions (indels) per megabase of tumour genome examined.^{11 14}

With a variety of alternative approaches now available, standardisation is required as TMB assays move into clinical practice. It is essential to raise awareness of all assay considerations to ensure that reliable and accurate TMB assessments can be achieved and compared across studies.

Rationale for TMB as a biomarker for response to immunotherapy

Evidence suggests that tumours with higher TMB also carry higher neoantigen loads.¹⁶ Tumour-specific somatic mutations can give rise to neoantigens, which are novel protein epitopes specific to tumours that may be presented on the tumour cell surface by major histocompatibility complex molecules.^{10 17 18} A subset of neoantigens can be recognised as 'non-self', leading to T-cell activation and a tumour-targeted immune response.^{19 20} The clonal nature of tumour evolution implies that T-cell-activating neoantigens will be propagated.²¹ T-cell receptor sequencing shows that increased clonal neoantigen load may drive clonal T-cell expansion and a sustained antitumour immune response.^{4 10 22 23}

Immune checkpoint molecules negatively regulate T-cell activation, leading to suppression of neoantigen-driven immune responses and allowing tumours to escape immune surveillance.¹⁶ Immune checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, and anti-cytotoxic T-lymphocyte antigen 4, restore the antitumour immune response,^{4 24} and neoantigen-driven activation of the antitumour immune response implies that tumours with high TMB are more likely to respond to immune checkpoint blockade.^{16 24–26} Moreover, clonal tumour evolution and the effects of increased T-cell activity on other tumour properties may further increase sensitivity to immunotherapy.^{10 21 27 28}

TMB and neoantigen load vary considerably within and across tumour types, with melanomas, lung cancers, and bladder cancers being among those with the highest TMB compared with other tumour types (figure 1).^{11 29–33} The mutational landscape can also vary across the tumour and evolve during tumour development or following treatment.^{22 34}

Tumours with high TMB may exhibit specific genetic alterations associated with clinical benefit to immunotherapy.^{35 36} For example, high TMB can be caused by defects in mismatch repair (MMR) genes that are associated with microsatellite instability (MSI).^{11 16 26} The MMR pathway is responsible for the correction of DNA

replication errors; such errors frequently occur in microsatellites (short tandem DNA repeats found across the genome). Mutations in MMR genes can lead to increased mutational incidence within microsatellites; MSI can therefore be a surrogate marker for DNA repair disorders, such as deficient mismatch repair (dMMR).³⁷ Similarly, DNA polymerase epsilon (POLE) is required for high-fidelity DNA replication, ensured by Watson–Crick base pairing and exonuclease (proofreading) activity. Mutations in the exonuclease domain of POLE can cause a hypermutator or ultramutator phenotype with TMB >10 mut/Mb or >100 mut/Mb, respectively.³⁸

While clonal tumour expansion may not increase TMB, POLE mutant, dMMR, and MSI-high tumours have been associated with high TMB. However, the reverse is not always true. For example, melanoma and lung tumours frequently have high TMB but <1% are MSI-high^{39 40} and POLE deficiency occurs in <3% of lung cancers,⁴¹ indicating that other mechanisms, including pathogenic events such as UV exposure or smoking, contribute to increased TMB in these tumour types.^{11 15 38 42} Testing for driver mutations should therefore occur alongside TMB.^{35 43} Nevertheless, immunotherapy has demonstrated clinical benefit for patients with dMMR and MSI-high tumours,^{30 44–48} further supporting that TMB, as a surrogate for genome instability as well as tumour neoantigens, is an appropriate biomarker for response to immunotherapy.

Overview of TMB assays and assay variations

NGS approaches

TMB assessment by NGS can involve WGS, WES, or large targeted gene panels, yet analytical and bioinformatic methods are not standardised across research or clinical studies. Both coding and non-coding sequences are analysed in WGS, but because only coding sequences are relevant for TMB assessment, WES, covering the entire exome, and gene panels, covering selected regions, are each suitable.^{10 16} Gene panels differ in input sample requirement, gene number or identity, region covered, workflow, and bioinformatic algorithms used (table 2); variation in TMB can arise from one or more of these parameters.¹¹

For most studies to date demonstrating an association between TMB and clinical benefit, TMB was measured by WES. However, it is challenging to routinely implement WES in a clinical setting because this method typically requires complex analysis and a matched normal sample for germline comparisons.^{11 47 49 50} Interoperability of data by WES is influenced by tumour heterogeneity, artefacts related to tissue preparation of formalin-fixed, paraffin-embedded (FFPE) samples, and discrepancies across assays available from commercial vendors.⁵¹

Targeted gene panels have been developed as an alternative method to WES. Whereas WES provides sequence coverage across the entire exome, gene panels are focused on large numbers of cancer-related genes and coupled to bioinformatic algorithms that rapidly




Figure 1 Distribution of TMB and neoantigen load across tumour types. (A) TMB and corresponding predicted neoantigen variation across 14 different tumour types. Data derived from Chen *et al.*²⁶ (B) TMB variation across 30 different tumour classes. Adapted with permission from Springer: Alexandrov LB, Nik-Zainal S, Wedge DC, *et al.* Signatures of mutational processes in human cancer. *Nature* 2013;500(7463):415–21;³⁰ Copyright 2013. AD, adenocarcinoma; ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia; SCLC, small cell lung cancer; SQ, squamous cell carcinoma; TMB, tumour mutational burden.

report on cancer-targeted genomic alterations, such as copy number alterations (eg, human epidermal growth factor receptor 2 (*ERBB2*)), gene rearrangements (eg, anaplastic lymphoma kinase (*ALK*)), MSI, and TMB, along with identification of specific cancer-associated mutations (eg, epidermal growth factor receptor (*EGFR*^{T790M})).^{13–14} Therefore, comprehensive genomic profiling using gene panels can provide targeted information that may not be immediately available in WES data. Three gene panel tests (FoundationOne, FoundationOne CDx, and MSK-IMPACT) have documented good concordance with TMB assessment by WES using both empirical and in silico approaches.^{15–55}

Therefore, gene panels potentially provide an effective approach for TMB estimation in clinical practice.^{11–15, 49–50, 56}

Further concordance studies are needed to bridge TMB data from WES to gene panels, and translation studies aim to create a framework to define common TMB assay parameters and harmonise data between different gene panels. Ongoing studies by the Quality Assurance Initiative Pathology (QuIP) operated by the German Society of Pathology and the Federal Association of German Pathologists, The Friends of Cancer Research, and the International Quality Network for Pathology (IQN Path) together with the European Society of Medical Oncology

Table 2 Examples of NGS gene panels in development or currently available to assess TMB

Status	Test name	Number of genes	Coverage (Mb)*	Gene variants	Sample type
FDA-approved or authorised diagnostic assays†	MSK-IMPACT ^{15 56 68}	468	1.5	SNVs, indels, rearrangements/fusions, CNAs, parallel analysis of genomic signatures (eg, TMB and dMMR/MSI)	FFPE
	Foundation Medicine FoundationOne CDx ^{14 49}	324	0.8	SNVs, indels, CNAs, select rearrangements, parallel analysis of genomic signatures (eg, TMB and dMMR/MSI)	FFPE
Commercial assays for research use only	Caris Molecular Intelligence ¹³²	592	1.4	Somatic missense mutations	FFPE
	Illumina TruSight 500 gene panel ¹³³	500	2.0	SNVs and indels	FFPE
	Thermo Fisher Scientific OncoPrint Tumor Mutation Load Assay ⁷⁷	409	1.7	SNVs	FFPE
	NEO New Oncology NEOplus v2 RUO ¹³⁴	>340	1.1	SNVs, indels, fusions, CNAs, parallel analysis of TMB, MSI, and driver mutations	FFPE
	Foundation Medicine FoundationOne ⁵⁰	315	1.1	SNVs, indels, CNAs, select gene rearrangements, genomic signatures for MSI and TMB	FFPE
	Foundation Medicine bTMB assay ^{88 122}	394	1.1	SNVs	Blood
	TruSight Tumor 170 ¹³⁵	170	0.5	Fusions, splice variants, SNVs, indels, amplifications	FFPE
	QIAGEN GeneRead DNAseq Comprehensive Cancer Panel ⁹⁷	160	0.7	SNVs, CNAs, indels, and fusions	FFPE
	NEO New Oncology NEOplus ^{105 136}	94		SNVs, indels, CNAs, rearrangements, and fusions	FFPE

*Exonic breadth of coverage for the above assays is incomplete because public information may not be available for some assays.

†FoundationOne CDx has FDA premarket approval for mutations associated with several targeted therapies. In addition, FoundationOne CDx can provide tumour mutation profiling to be used by qualified healthcare professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.¹³⁷ MSK-IMPACT is FDA-authorised to provide information on somatic mutations and MSI. TMB is captured as part of the enhanced report and is considered for investigational use only.^{13 15} CNA, copy number alteration; dMMR, mismatch repair deficiency; FFPE, formalin-fixed, paraffin-embedded; MSI, microsatellite instability; Mb, megabases; NGS, next-generation sequencing; SNV, single nucleotide variant; TMB, tumour mutational burden.

(ESMO), are essential for the standardisation of TMB assessment.^{57–60}

TMB panel size

The size of the genome area sequenced differs across assays. WES covers the coding regions of all ~22 000 genes (~180 000 exons, equivalent to 30 Mb), making up ~1% of the genome⁶¹ and encompassing most of the known disease-causing variants. FoundationOne CDx and MSK-IMPACT assays cover ~0.8 Mb over 324 genes and ~1.5 Mb over 468 genes, respectively.^{14 62} Some evidence suggests that smaller gene panels may be sufficient for TMB assessment,⁶³ but other evidence indicates that they may only be sufficient to detect hypermutated and ultramutated tumours and that larger gene panels may be more accurate overall.^{54 64} Tumours with high TMB may be effectively identified by targeted

sequencing of several hundred genes, and accuracy may not increase significantly above this threshold.^{11 36 56} However, variance increases significantly below 0.5 Mb, particularly in samples with low TMB.^{11 64} For clinical purposes, evidence suggests that gene panels of ≥0.8 Mb are needed.^{14 64}

It is important to consider whether the specific gene sequences in a panel have an impact on the TMB result. Panels targeted to specific cancer-related genes may introduce unwanted bias into the area of genome covered, but if the panel is sufficiently large, then the function of specific genes within it should be negligible and not impact TMB assessment. There are, of course, driver mutations, such as *BRCA1*, *TP53*, and *POLE*, that are associated with large increases in TMB^{11 15 38 65} and these should be assessed alongside TMB.^{46 66}

Depth of coverage

Alongside sequencing breadth, sequencing depth (the average number of reads that align to a known reference base⁶⁷) is also variable across NGS assays. The typical sequencing depth for WES is ~100×, and only mutations with allele frequencies of >15% can be detected with confidence.⁵¹ The typical sequencing depth for a gene panel is greater at 500×, increasing the likelihood of detecting low-frequency variants at specific loci,^{68 69} although the minimum depth of coverage required for accurate TMB assessment may be closer to 200×.⁷⁰ Together, breadth and depth of coverage may impact the sensitivity and specificity of TMB assessment, but strong evidence suggests that gene panels may be adequate to provide a reliable TMB measurement if sequencing quality thresholds are upheld.

Variant calling

A number of calculations and filters are employed downstream of sequencing to include or discard variants in the TMB estimation. The bioinformatic algorithms used are often not publicly reported, but may differ across assays and may impact TMB output.¹¹ Understanding and harmonising these bioinformatic elements are essential.

One important consideration is the types of mutations included in the assessment, such as insertion and deletion alterations (indels), and base substitutions/single nucleotide variants (which can include synonymous and nonsynonymous mutations).^{11 15 49 50 71} TMB assessment by WES or gene panels commonly includes nonsynonymous somatic tumour mutations, but these may be restricted to missense mutations only. Recent evidence suggests that outcomes following immunotherapy are more strongly associated with TMB that is defined as including nonsynonymous mutations than with TMB that includes both synonymous and nonsynonymous mutations.³⁵ However, some studies using smaller gene panels may also include synonymous mutations to ensure a representative TMB estimate.^{10 11 15 30} Another consideration is the variant allele frequency (VAF) cut-offs used to ensure that TMB is a reliable estimation of the number of mutations in the tumour, with minimal artefacts from sequencing errors, formalin-induced DNA damage, or sample contamination.^{72 73} Variant calling may be improved by capturing and sequencing both DNA strands in the target sequence.⁷⁴ In studies using WES, VAF can vary from 5% to 10%.^{75 76} FoundationOne CDx and OncoPrint assays call all variants with a VAF ≥5%,^{14 77} and MSK-IMPACT calls those ≥2% for mutation hotspots and ≥5% for nonhotspots.¹³ TMB reporting adds a further level of complexity when comparing TMB across studies, as most studies report TMB as mut/Mb, whereas others report TMB as total mutations per tumour.

Somatic variants

It is important to distinguish between tumour-specific acquired (somatic) mutations and those that are present in normal tissue (also known as germline mutations). For

WES and MSK-IMPACT, paired sample mutation calling is typically performed on tumour samples and matched germline control (blood) samples.^{11 13 15} Using control samples for assessment of germline variants may not be feasible, practical, or even legal, because germline testing may have further-reaching implications outside cancer diagnosis.^{78–80} Somatic mutations can be inferred in tumours without matched controls in silico from databases of known polymorphisms or variant data in tissue from different patients.^{11 14 54 81} Some assays filter potential germline mutations using a somatic-germline zygosity algorithm, which identifies the origin of the mutation by leveraging allele frequencies and genome-wide copy number.^{11 14 82} Although these approaches simplify the TMB assessment workflow, they may result in false positives and higher TMB, particularly in patients with ethnic backgrounds that are less well represented in reference databases.^{11 54} These effects may be negligible for TMB assessment by WES or large gene panels, but increased in smaller panels.⁵⁴

Defining TMB thresholds

TMB thresholds were initially defined retrospectively in exploratory analyses of immunotherapy efficacy, with patients being grouped by TMB tertile or quartile^{35 52 83–85} or by numeric cut-offs, such as 100 or 178 mutations per exome^{22 36 86} or 9–20 mut/Mb.^{11 87 88} To date, the TMB threshold of ≥10 mut/Mb, measured by FoundationOne CDx (equivalent to ~200 mutations by WES) in first-line patients with non-small cell lung cancer (NSCLC), is the only cut-off established for enhanced response to immunotherapy in one trial and clinically validated in a separate study using a preplanned approach.^{8 9 55}

Identifying a single, fixed TMB threshold that could be applicable across different tumours may be difficult, because the median number of somatic mutations differs across tumour types (figure 1).^{26 30} In silico analyses suggested that clinical response in NSCLC and melanoma may increase and then plateau at ~260 nonsynonymous mutations (measured by WES),³¹ but this prediction would need stringent validation to determine which types of mutations contributed to this number and how to translate this value into other patient groups. Further studies evaluating a clinically validated TMB cut-off will be instrumental in providing an agreed TMB cut-off within particular tumour types. Increased use of specific approved commercial assays will also assist in cross-trial comparisons.

Considerations for sample preparation and TMB assays

Samples used for TMB assessment may be cytology or liquid biopsies, or FFPE tumour tissue. Although some evidence exists for the feasibility of using cytology and fine-needle aspiration for analysis by NGS,^{89 90} these samples can yield variable amounts of DNA that may not always be sufficient for in-depth molecular analysis.^{91 92} FFPE samples are the most commonly available patient samples for clinical testing. FFPE slides and extracted DNA are

reliable for TMB assessment for 6 months and likely beyond.¹⁴ However, FFPE samples present a risk for use with high-throughput genomic assays, because preanalytical factors common to NGS testing can affect the sample integrity or amount of DNA that can be extracted.^{72 73 93 94} These factors include clinical sample availability; sample collection, preparation, and fixation (optimally 24 hours in neutral buffered formalin for surgical specimens and 12 hours for biopsies^{95 96}); neoplastic cell content in the sample; batch processing; and ensuring sufficient DNA quality and yield for assessment (10–100 ng for gene panels and around 250 ng for WES).^{14 62 97–100} Insufficient DNA is a common cause of sample attrition in clinical trials,^{52 101} so assays that require less DNA may be advantageous.

In addition to variability in sample handling, technical processes and working practices employed by clinical laboratories can vary extensively.¹⁰² Specifically, centralised and decentralised laboratories differ in infrastructure, equipment, and gene panels used, and different platforms may vary in bioinformatic workflow, data integration, and/or how the data are reported.^{47 103 104}

TMB from liquid biopsies

Interest in isolating cell-free DNA (cfDNA) from liquid biopsies for assessment of circulating tumour DNA (ctDNA) is increasing because of the less invasive nature of sample collection from patients and greater opportunity for obtaining frequent samples. TMB measurements from cfDNA may have advantages over tissue biopsy in the follow-up of early responses to immunotherapy due to the ease and speed of obtaining them.¹⁰⁵ TMB assays that use cfDNA have been developed and validated, with ongoing efforts for harmonisation with TMB data from tissue samples.^{87 106–109} Data for TMB concordance between tissue and cfDNA by gene panel assays are conflicting, with reports of both good concordance¹¹⁰

and a lack of concordance.¹¹¹ Some studies have demonstrated that the sensitivity of detecting mutations from cfDNA is decreased compared with solid tumour samples for both WES and gene panels, although the correlation between TMB assessed from tissue and cfDNA is greater by WES than a panel.^{75 105 107} Liquid biopsies may yield a variable mix of normal and tumour DNA, and the tumour DNA could reflect heterogeneity across different tumour sites. Thus, variable data exist for concordance between solid and liquid samples, and there is a need for further studies. Nevertheless, future clinical use of TMB assessment from liquid biopsies remains feasible.

Turnaround time

Alongside technical specifications of the tests, other regulatory, practical, and logistic factors are important, such as assay turnaround time, runtime, and cost. Turnaround time is impacted by the time required for steps in the workflow and, therefore, the availability of key stakeholders to carry out their role in the generation of a reliable TMB result (figure 2). Given the comprehensive nature of the assay, it is difficult to balance turnaround time with cost, and microcosting analyses are urgently needed.¹¹² The common turnaround time for TMB assessment by commercial assays is approximately 2 weeks, including 4–5 days of library preparation time.^{14 69} Moving forward, there is a need to establish acceptable TMB assay turnaround times, especially if the test is applied in the first-line cancer setting. A test for both actionable mutations and TMB is preferable for first-line patients. Moreover, TMB is a surrogate marker for neoantigen load, which may impact immune response and response to therapy, and studies monitoring TMB suggest that follow-up testing could detect residual disease or recurrence.^{21 22 113}




Figure 2 Biopsy sample workflow for TMB testing. A proposed, optimised workflow is shown to streamline diagnostic testing for TMB alongside other genomic markers. *ALK*, anaplastic lymphoma kinase; CNA, copy number alteration; *EGFR*, epidermal growth factor receptor; MSI, microsatellite instability; NGS, next-generation sequencing; QC, quality control; *ROS*, ROS proto-oncogene 1, receptor tyrosine kinase; TMB, tumour mutational burden.

Quality assurance

Multidisciplinary teams are involved in oncology sampling and diagnostics, from sample collection by the surgeon through to TMB assay result interpretation (figure 2). There is a need for all to be coordinated and well informed on the necessary approaches to achieve a reliable assay result, and molecular tumour boards have been set up to ensure global harmonisation in tumour-sequencing practices.¹¹⁴ Recent NGS guidelines from pathologists emphasise the role of the laboratory director in using an error-based approach that can identify potential sources of errors that may occur throughout the analytical process.⁷²

The robustness of a TMB assessment method, reflected by its approval status (FDA, CLIA, CE-IVD approved, or for research use only), is likely to influence the choice of assay used in clinical practice. Many steps within the TMB assessment pathway can vary and their impact should be assessed. For example, changing an extraction protocol may pose a minor risk if quality control is in place to verify sample purity and concentration; however, changes to which NGS platform is used are likely to require a new validation process.⁷² Appropriately trained personnel at each step of the workflow to carry out quality-control processes will minimise variance and impact.⁷²

Table 3 Key parameters for the harmonisation of TMB analysis and workflow

Parameter	Principles
Sample	<ul style="list-style-type: none"> ▶ Sample must provide adequate quantity and quality of DNA ▶ Most cancer NGS assays are performed on FFPE tissue (optimal fixation time, 24 hours for surgical specimens and 12 hours for biopsies). Cytology/FNA, plasma, and other types of samples may be acceptable for smaller targeted panels and are in development to be established for use in the future
Methodology	<ul style="list-style-type: none"> ▶ WES is considered the gold standard for measuring TMB because it offers high breadth of coverage compared with gene panels ▶ Investigations of smaller gene panels are ongoing for TMB assessment ▶ In general, larger panels have been shown to be more accurate than smaller panels. As more data become available, there may be a recommended number of genes to profile for optimised gene profiling/TMB; current recommendations indicate that the area of genome covered should be >0.8 Mb (preferably >1 Mb) ▶ Screening for driver mutations (eg, <i>EGFR</i>, <i>BRAF</i>, <i>KRAS</i>) and TMB in one assay is recommended to avoid time delays or processing of multiple samples. Inclusion of driver mutations, rearrangements, etc on the panel can provide additional clinical utility for the assay beyond TMB, but may not necessarily be informative for the TMB calculation ▶ Sequencing depth can affect detection of low-frequency variants. ≥200× is recommended
Platforms	<ul style="list-style-type: none"> ▶ Stakeholders should be aware of varying parameters such as runtime and throughput capacity of available sequencers
Germline	<ul style="list-style-type: none"> ▶ Experimental approaches by filtering germline variants with matched normal samples ▶ In silico approaches by filtering against germline variant databases
Algorithm	<ul style="list-style-type: none"> ▶ Standardised and robust bioinformatic pipelines should be developed ▶ There is a need for internationally available reference standards (ie, sets of tumours with WES data) ▶ Variant allele frequency cut-offs should be reported. Cut-offs of ≥5% are recommended
Cut-off	<ul style="list-style-type: none"> ▶ Currently no standard cut-off to designate high TMB and there is a need for harmonisation of tests to establish set thresholds. More standardised cut-offs are anticipated as clinical utility is established for individual tumour types and TMB thresholds are studied in the context of response to immunotherapies ▶ TMB thresholds of ≥13 mut/Mb and ≥10 mut/Mb, measured by FoundationOne CDx, have recently been associated with enhanced responses to immune checkpoint inhibitor monotherapy and combination therapy, respectively, in patients with non-small cell lung cancer. The value cut-off ≥10 mut/Mb was established in one study and clinically validated in a separate trial.^{8,9} In patients with small cell lung cancer, improved responses were seen with a cut-off of ≥248 missense mutations, as measured by WES⁸⁴
Concordance	<ul style="list-style-type: none"> ▶ Recommendations on validation processes and concordance testing with WES for approved gene panels or other commercial panels without clinical data ▶ Need for direct comparison between panels (especially for FDA-approved or authorised panels)
Reporting	<ul style="list-style-type: none"> ▶ Reporting standards for how TMB is defined and calculated, including gene panel number, capture region, control (germline subtraction), types of mutations called, variant calling threshold, and sequence depth ▶ Recommend reporting results as mutations per megabase of targeted DNA ▶ Recommend accurate reporting of TMB thresholds and highlight associated clinical outcomes ▶ Quality assurance on data reporting is also required

BRAF, B-Raf proto-oncogene, serine/threonine kinase; *EGFR*, epidermal growth factor receptor; FFPE, formalin-fixed, paraffin-embedded; FNA, fine-needle aspiration; *KRAS*, *KRAS* proto-oncogene, GTPase; mut/Mb, mutations per megabase; NGS, next-generation sequencing; TMB, tumour mutational burden; WES, whole exome sequencing.

As TMB becomes more established, an increase in the number of commercial or LDT panels is anticipated. Recommendations for how to implement TMB assays will be developed further with input from the international harmonisation efforts described above. It is therefore important to understand how LDTs can augment TMB testing. The identification of reference standards or external quality evaluation is a way to compare LDTs with other methods. It is likely that the clinical evidence for robust TMB assessment will be limited to a few key assays, with a need for calibration and concordance studies to facilitate the transition from clinical trials to the real-world setting.

Challenges and solutions to adopting TMB assays in clinical practice

Because data have demonstrated that high TMB is a predictive marker for clinical benefit from immunotherapy, the ability to classify TMB as high or low is essential for predicting response. Defining cut-offs for TMB may directly lead to inclusion or exclusion of some patients from treatment. However, most published clinical studies of TMB to date have been exploratory, using a number of different methods, and it is challenging to compare data across studies. The availability of preanalytic, sequencing, and bioinformatic protocols will help to harmonise TMB estimation with clinical outcomes.

Lessons can also be learnt from experiences with PD-L1 expression testing. The need for sample quality control, concordance studies across PD-L1 testing platforms to determine the interchangeability of tests, and appropriate training for key personnel to interpret the data are all applicable for any biomarker. Even though TMB outputs are based on computational assessment, there is still a need for education and training on how these values are derived.

With PD-L1 expression and TMB as independent and potentially complementary predictive markers for response to immunotherapy,⁵² questions turn to the possible need for coordinated multiparameter or composite testing to continue to advance the field. Interplay between TMB, PD-L1, tumour-infiltrating lymphocytes, and cytolytic activity is emerging from comprehensive immunogenomic analyses,²⁶ raising the possibility of composite biomarker testing within the tumour microenvironment.

CONCLUSIONS

Validated predictive biomarkers should accurately predict patient responses to immunotherapy. The use of TMB assessment has been actively addressed by ongoing studies, including those clinically validating TMB as a biomarker for response to immunotherapy. Using valuable lessons learnt from PD-L1 testing, including the need for concordance studies across testing platforms and the need for trained personnel to assess the assay

results, the development of TMB as a clinical diagnostic tool is being defined.

As the field evolves, solutions emerge to ensure that reliable TMB assessments are carried out in clinical practice. However, definitive recommendations may not be possible until more data are available from prospective clinical trials. From the knowledge gained so far, key parameters can be highlighted throughout the TMB testing workflow, including collection of samples, methods, and analysis (table 3). These include current suggestions to use solid tissue samples, to use gene panels with a coverage >0.8 Mb (preferably >1 Mb), to ensure sufficient information is given when reporting TMB values (including number of genes, capture region, germline subtraction, types of mutations called, variant calling threshold, and sequence depth^{72 103}), to participate in external quality-control schemes when available and to ensure trained stakeholders are available for efficient workflow and assay interpretation.

It will be necessary to accumulate larger datasets, set minimal tissue sample purity thresholds, and standardise sample processing and robust bioinformatic pipelines such that TMB can be calculated in a reliable manner.^{1 11 99 115 116} Further analyses will also be required to understand how biomarkers, such as TMB, PD-L1, and other genetic/immune markers, interact.

Despite method variability, scoring the number of somatic mutations in tumour DNA is relatively simple, and exhaustive characterisation of tumours will increase understanding of their characteristics. As momentum for TMB as a biomarker of immunotherapy response increases and standardised approaches begin to emerge to allow for clinical implementation, it is likely that TMB assessment, with or without additional biomarkers, will be at the forefront of precision medicine in the foreseeable future.

Contributors All authors contributed to writing the manuscript and approved the final version.

Funding Medical writing support and editorial assistance were provided by Stuart Ruiten, PhD, and Jay Rath, MA, of Spark Medica Inc, funded by Bristol-Myers Squibb, according to Good Publication Practice guidelines.

Competing interests ER reports personal fees and non-financial support from AstraZeneca and Bristol-Myers Squibb. JL reports grants from Agilent Technologies and Roche Tissue Diagnostics, and personal fees from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Pfizer, and Roche Tissue Diagnostics. FL-R reports personal fees from AstraZeneca, Bristol-Myers Squibb, Life Technologies, Merck, Pfizer, and Roche. FP-L reports grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Merck, and Roche, and grants from NanoString. NN reports grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Qiagen, Roche, and Thermo Fisher Scientific, and grants and non-financial support from Merck. SM-B reports grants and personal fees from AstraZeneca and Novartis, and personal fees from Bristol-Myers Squibb and Roche. RB declares no conflicts of interest.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0>

REFERENCES

- Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. *Lancet Oncol* 2016;17:e542–e551.
- Mehnert JM, Monjazeb AM, Beerthuijzen JMT, et al. The challenge for development of valuable immuno-oncology biomarkers. *Clin Cancer Res* 2017;23:4970–9.
- Hersom M, Jørgensen JT. Companion and complementary diagnostics-focus on PD-L1 expression assays for PD-1/PD-L1 checkpoint inhibitors in non-small cell lung cancer. *Ther Drug Monit* 2018;40:9–16.
- Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). *Ann Oncol* 2016;27:1492–504.
- Büttner R, Gosney JR, Skov BG, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. *J Clin Oncol* 2017;35:3867–76.
- Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. *JAMA Oncol* 2017;3:1051–8.
- Voong KR, Feliciano J, Becker D, et al. Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. *Ann Transl Med* 2017;5:376.
- Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med* 2018;378:2093–104.
- Ramalingam S, Hellmann MD, Awad M. Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568. Presented at the AACR Annual Meeting, Chicago, IL, 2018.
- Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science* 2015;348:69–74.
- Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med* 2017;9:34.
- FDA. FDA announces approval, CMS proposes coverage of first breakthrough-designated test to detect extensive number of cancer biomarkers. 2017. Available from: <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587273.htm>
- FDA. FDA unveils a streamlined path for the authorization of tumor profiling tests alongside its latest product action. 2018. Available from: <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585347.htm>
- FDA. FoundationOne CDx: Summary of Safety and Effectiveness Data (SSED). 2018. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf
- Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med* 2017;23:703–13.
- Chabannon RM, Pedrero M, Lefebvre C, et al. Mutational landscape and sensitivity to immune checkpoint blockers. *Clin Cancer Res* 2016;22:4309–21.
- Gilboa E. The makings of a tumor rejection antigen. *Immunity* 1999;11:263–70.
- Łuksza M, Riaz N, Makarov V, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. *Nature* 2017;551:517–20.
- Geyer RJ, Tobet R, Berlin RD, et al. Immune response to mutant neo-antigens: Cancer's lessons for aging. *Oncoimmunology* 2013;2:e26382.
- Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. *Embo J* 2013;32:194–203.
- McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science* 2016;351:1463–9.
- Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. *Cell* 2017;171:934–49.
- Weber J, Horak C, Hodi FS, et al. Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab. *Ann Oncol* 2016;27:10470.
- Liontos M, Anastasiou I, Bamias A, et al. DNA damage, tumor mutational load and their impact on immune responses against cancer. *Ann Transl Med* 2016;4:264.
- Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. *N Engl J Med* 2017;377:2500–1.
- Chen YP, Zhang Y, Lv JW, et al. Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: Immunotherapeutic implications. *Theranostics* 2017;7:3585–94.
- Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. *Cell* 2015;160:48–61.
- Coulie PG, Van den Eynde BJ, van der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. *Nat Rev Cancer* 2014;14:135–46.
- Grivas PD, Melas M, Papavassiliou AG. The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches. *Semin Cancer Biol* 2015;35:125–32.
- Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. *Nature* 2013;500:415–21.
- Colli LM, Machiela MJ, Myers TA, et al. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses. *Cancer Res* 2016;76:3767–72.
- Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. *Nature* 2013;502:333–9.
- Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 2013;499:214–8.
- Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. *N Engl J Med* 2017;376:2109–21.
- Hellmann MD, Nathanson T, Rizvi H, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. *Cancer Cell* 2018;33:843–52.
- Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015;348:124–8.
- Buecher B, Cacheux W, Rouleau E, et al. Role of microsatellite instability in the management of colorectal cancers. *Dig Liver Dis* 2013;45:441–9.
- Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer. *Cell* 2017;171:1042–56.
- Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. *JCO Precis Oncol* 2017;2017:1–15.
- Takamochi K, Takahashi F, Suehara Y, et al. DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. *Lung Cancer* 2017;110:26–31.
- Song Z, Cheng G, Xu C, et al. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. *Lung Cancer* 2018;118:57–61.
- Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409–13.
- Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. *Cancer Discov* 2018;8:822–835.
- Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015;372:2509–20.
- Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. *Cell* 2016;165:35–44.
- Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science* 2018;359:801–6.
- Viale G, Trapani D, Curigliano G. Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. *Biomed Res Int* 2017;2017:4719194.
- Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. *JAMA Oncol* 2018;4:e180013.
- Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. *Nat Biotechnol* 2013;31:1023–31.
- Campesato LF, Barroso-Sousa R, Jimenez L, et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. *Oncotarget* 2015;6:34221–7.
- Qiu P, Pang L, Arreaza G, et al. Data interoperability of whole exome sequencing (WES) based mutational burden estimates from different laboratories. *Int J Mol Sci* 2016;17:651.

52. Carbone DP, Reck M, Paz-Ares L, *et al.* First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. *N Engl J Med* 2017;376:2415–26.
53. Johnson DB, Frampton GM, Rioth MJ, *et al.* Targeted next generation sequencing identifies markers of response to PD-1 blockade. *Cancer Immunol Res* 2016;4:959–67.
54. Garofalo A, Sholl L, Reardon B, *et al.* The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. *Genome Med* 2016;8:79.
55. Szustakowski JD, Green G, Geese WJ, *et al.* Evaluation of tumor mutation burden as a biomarker for immune checkpoint inhibitor efficacy: a calibration study of whole exome sequencing with FoundationOne®. *Presented at the AACR Annual Meeting*, Chicago, IL, 2018.
56. Rizvi H, Sanchez-Vega F, La K, *et al.* Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. *J Clin Oncol* 2018;36:633–41.
57. Tkach Tuzman K. Shared burden: how tests developers are seeking harmony for tumor mutational burden assays. 2018. Available from: <https://www.biocentury.com/bc-innovations/tools-techniques/2018-03-15/how-test-developers-are-seeking-harmony-tumor-mutational-burden/>
58. Deans ZC, Costa JL, Cree I, *et al.* Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours: an expert opinion on behalf of IQN Path ASBL. *Virchows Arch* 2017;470:5–20.
59. van Krieken H, Deans S, Hall JA, *et al.* Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016. *ESMO Open* 2016;1:e000114.
60. IQN Path. International quality network for pathology. Annual Report. 2017. Available from: http://www.iqnpath.org/wp-content/uploads/2018/04/IQNPath_AnnualReport2017-26032018.pdf
61. Ng SB, Turner EH, Robertson PD, *et al.* Targeted capture and massively parallel sequencing of 12 human exomes. *Nature* 2009;461:272–6.
62. FDA. Evaluation of Automatic Class III Designation for MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets): decision summary. 2018. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170058.pdf
63. Yourstone S, Mola N, Weigman VJJ. Effects of sequencing parameters and panel size on mutational burden calculations. *Presented at the AACR Annual Meeting*, Chicago, IL, 2018.
64. Baras AS, Stricker T. Characterization of total mutational burden in the GENIE cohort: Small and large panels can provide TMB information but to varying degrees. *Cancer Res* 2017;77:LB-105.
65. Spigel DR, Schrock AB, Fabrizio D, *et al.* Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. *J Clin Oncol* 2016;34:9017.
66. Chaudhuri A, Chabon JJ, Lovejoy AF, *et al.* Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies. *J Clin Oncol* 2017;35:8519.
67. Sims D, Sudbery I, Iltott NE, *et al.* Sequencing depth and coverage: key considerations in genomic analyses. *Nat Rev Genet* 2014;15:121–32.
68. Cheng DT, Mitchell TN, Zehir A, *et al.* Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. *J Mol Diagn* 2015;17:251–64.
69. Feliubadaló L, Tonda R, Gausachs M, *et al.* Benchmarking of whole exome sequencing and ad hoc designed panels for genetic testing of hereditary cancer. *Sci Rep* 2017;7.
70. Lee C, Bae JS, Ryu GH, *et al.* A method to evaluate the quality of clinical gene-panel sequencing data for single-nucleotide variant detection. *J Mol Diagn* 2017;19:651–8.
71. Singh RR, Patel KP, Routbort MJ, *et al.* Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. *J Mol Diagn* 2013;15:607–22.
72. Jennings LJ, Arcila ME, Corless C, *et al.* Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. *J Mol Diagn* 2017;19:341–65.
73. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. *Am J Pathol* 2002;161:1961–71.
74. Moens LN, Falk-Sörqvist E, Ljungström V, *et al.* HaloPlex targeted resequencing for mutation detection in clinical formalin-fixed, paraffin-embedded tumor samples. *J Mol Diagn* 2015;17:729–39.
75. Koeppel F, Blanchard S, Jovelet C, *et al.* Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. *PLoS One* 2017;12:e0188174.
76. Lauss M, Donia M, Harbst K, *et al.* Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. *Nat Commun* 2017;8:8.
77. ThermoFisher. ThermoFisher OncoPrint™ tumor mutation load assay user guide. 2018. Available from: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0017042_TumorMutLoad_UG.pdf
78. Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. *Cancer Biol Med* 2016;13:3–11.
79. Robson ME, Bradbury AR, Arun B, *et al.* American Society of Clinical Oncology Policy Statement Update: genetic and genomic testing for cancer susceptibility. *J Clin Oncol* 2015;33:3660–7.
80. Robson ME, Storm CD, Weitzel J, *et al.* American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. *J Clin Oncol* 2010;28:893–901.
81. Tian Y, Jones W, Mola N. TMB calling in absence of matched normal: learning germline behavior. *Presented at the AACR Annual Meeting*, Chicago, IL, 2018.
82. Sun JX, He Y, Sanford E, *et al.* A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. *PLoS Comput Biol* 2018;14:e1005965.
83. Galsky MD, Saci A, Szabo PM, *et al.* Impact of tumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase II CheckMate 275 study. *Ann Oncol* 2017;28:v295–v329.
84. Antonia S, Callahan MK, Awad MM, *et al.* Impact of tumor mutation burden on the efficacy of nivolumab or nivolumab + ipilimumab in small cell lung cancer: an exploratory analysis of CheckMate 032. *Presented at the IASLC 18th World Conference on Lung Cancer*, Yokohama, Japan, 2017.
85. Kowanetz M, Zou W, Shames D, *et al.* OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients. *J Thorac Oncol* 2017;12:S321–S322.
86. Snyder A, Makarov V, Merghoub T, *et al.* Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med* 2014;371:2189–99.
87. Fabrizio D, Lieber D, Malboeuf C, *et al.* A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab. *Presented at the AACR Annual Meeting*, Chicago, IL, 2018.
88. Gandara DR, Paul SM, Kowanetz M, *et al.* Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. *Nat Med* 2018;24:1441–8.
89. Stoy SP, Segal JP, Mueller J, *et al.* Feasibility of endobronchial ultrasound-guided transbronchial needle aspiration cytology specimens for next generation sequencing in non-small-cell lung cancer. *Clin Lung Cancer* 2018;19:230–8.
90. DiBardino DM, Rawson DW, Saqi A, *et al.* Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology. *Cytojournal* 2017;14:7.
91. Roy-Chowdhuri S, Chow CW, Kane MK, *et al.* Optimizing the DNA yield for molecular analysis from cytologic preparations. *Cancer Cytopathol* 2016;124:254–60.
92. Chen H, Luthra R, Goswami RS, *et al.* Analysis of pre-analytic factors affecting the success of clinical next-generation sequencing of solid organ malignancies. *Cancers* 2015;7:1699–715.
93. Zhang P, Lehmann BD, Shyr Y, *et al.* The utilization of formalin fixed-paraffin-embedded specimens in high throughput genomic studies. In *Int J Genomics. Hindawi Publishing Corporation* 2017;1926304.
94. Grizzle WE. Special symposium: fixation and tissue processing models. *Biotech Histochem* 2009;84:185–93.
95. Einaga N, Yoshida A, Noda H, *et al.* Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation. *PLoS One* 2017;12:e0176280.
96. Howat WJ, Wilson BA. Tissue fixation and the effect of molecular fixatives on downstream staining procedures. *Methods* 2014;70:12–19.

97. QIAGEN. GeneRead DNAseq targeted panels V2. 2018. Available from: <https://www.qiagen.com/us/shop/sample-technologies/dna/genomic-dna/generead-dnaseq-gene-panels-v2/?catno=NGHS-501X>
98. Kircher M, Kelso J. High-throughput DNA sequencing--concepts and limitations. *Bioessays* 2010;32:524–36.
99. Roh W, Chen PL, Reuben A, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. *Sci Transl Med* 2017;9:eaah3560.
100. Cree IA, Deans Z, Ligtenberg MJ, et al. Guidance for laboratories performing molecular pathology for cancer patients. *J Clin Pathol* 2014;67:923–31.
101. Al-Kateb H, Nguyen TT, Steger-May K, et al. Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). *Mol Oncol* 2015;9:1737–43.
102. Pant S, Weiner R, Marton MJ. Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. *Front Oncol* 2014;4:78.
103. Roy S, Coldren C, Karunamurthy A, et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists. *J Mol Diagn* 2018;20:4–27.
104. Roszik J, Haydu LE, Hess KR, et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. *BMC Med* 2016;14:168.
105. Müller JN, Falk M, Talwar J, et al. Concordance between comprehensive cancer genome profiling in plasma and tumor specimens. *J Thorac Oncol* 2017;12:1503–11.
106. Sholl LM. Next-generation sequencing from liquid biopsies in lung cancer patients: advances in comprehensive biomarker testing. *J Thorac Oncol* 2017;12:1464–6.
107. Khagi Y, Goodman AM, Daniels GA, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. *Clin Cancer Res* 2017;23:5729–36.
108. Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. *J Clin Oncol* 2018;36:1631–41.
109. Sato KA, Hachiya T, Iwaya T, et al. Individualized mutation detection in circulating tumor DNA for monitoring colorectal tumor burden using a cancer-associated gene sequencing panel. *PLoS One* 2016;11:e0146275.
110. Mehrotra M, Singh RR, Loghavi S, et al. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. *Oncotarget* 2018;9:10259–71.
111. Davis AA, Chae YK, Agte S, et al. Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA). *J Clin Oncol* 2017;35:e23028.
112. Sabatini LM, Mathews C, Ptak D, et al. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. *J Mol Diagn* 2016;18:319–28.
113. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature* 2017;545:446–51.
114. van der Velden DL, van Herpen CML, van Laarhoven HWM, et al. Molecular tumor boards: current practice and future needs. *Ann Oncol* 2017;28:3070–5.
115. Jamieson NB, Maker AV. Gene-expression profiling to predict responsiveness to immunotherapy. *Cancer Gene Ther* 2017;24:134–40.
116. Mola N, Schu M, Stieglmeier S, et al. Tumor mutational burden: guidelines for derivation and robustness of measurement. Presented at the AACR Annual Meeting, Chicago, IL, 2018.
117. Singal G, Miller PG, Agarwala V, et al. Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database. *Ann Oncol* 2017;28:v403–v427.
118. Bouffet E, Larouche V, Campbell BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. *J Clin Oncol* 2016;34:2206–11.
119. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science* 2015;350:207–11.
120. Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science* 2018;362:eaar3593.
121. Seiwert TY, Cristescu R, Mogg R, et al. Genomic biomarkers in relation to PD-1 checkpoint blockade response. *J Clin Oncol* 2018;36:25.
122. Fabrizio D, Malboeuf C, Lieber D, et al. Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST). *Ann Oncol* 2017;28:v22–v24.
123. Velcheti V, Kim ES, Mekhail T, et al. Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. *J Clin Oncol* 2018;36:12001.
124. Mok TSK, Gadgeel S, Kim ES, et al. Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC. *Ann Oncol* 2017;28:v460–v496.
125. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet* 2017;389:67–76.
126. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* 2016;387:1909–20.
127. Powles T, Lortet Y, Ravaud A, et al. Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study. *J Clin Oncol* 2018;36(6_suppl):409.
128. Snyder A, Nathanson T, Funt SA, et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. *PLoS Med* 2017;14:e1002309.
129. Rozenblum AB, Ilouze M, Dudnik E, et al. Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. *J Thorac Oncol* 2017;12:258–68.
130. Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther* 2017;16:2598–608.
131. Bonta I, Isac JF, Meiri E, et al. Correlation between tumor mutation burden and response to immunotherapy. *J Clin Oncol* 2017;35(15_suppl):e14579.
132. Hussain MA, Heath EI, Somer BG, et al. Spectrum of tumor mutational load (TML) in genitourinary cancers (GU CA). *J Clin Oncol* 2017;35(15_suppl):4535.
133. So AS, Kaplan S, Zhang S, et al. Accurate measurement of tumor mutation burden through tumor-only sequencing using a 500-gene panel. Presented at the AACR Annual Meeting, Chicago, IL, 2018.
134. New Oncology, 2018. Assays. Available: <http://www.newoncology.com/en/assays>
135. Trusight, Tumor 170. 2018. Available: <https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/trusight-tumor-170-data-sheet-1170-2016-017.pdf>
136. Menon R, Mariotti E, Mueller J, et al. PUB053 panel based hybrid capture sequencing assay to correlate mutational load with response to immunotherapy. *J Thorac Oncol* 2017;12:S147–S1479.
137. FDA. Approval of FoundationOne CDx - P170019. 2017. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf